Due to the increasing clinical relevance of resistance to the combinatorial treatment with BRAFV600E/K and MEK inhibitors, we next assessed the efficacy of the RSK inhibitor in melanoma cells with acquired dual resistance to vemurafenib and the MEK inhibitor trametinib (A375 RR, SKMel28 RR) (Supplementary Figure 2D). Here, MAP2K7 is linked to melanoma.